Work

Lorlatinib (Lorbrena), An ALK Inhibitor for Treating NSCLC

Year: 2022

Type: other

DOI: 10.1002/9781119847281.ch11

Authors: Ruby M. Aaron, Hayden K. Low, Benjamin T. Sokol, Amy B. Dounay

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296617526

Cites: 21

Cited by:

Related to: 10